The 8th Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Top 50 Selection has officially commenced. Technoderma Medicines, Inc . (hereinafter referred to as "Technoderma Medicines") was awarded a "Pioneer Enterprise" on the Top 50 list and "2025 Annual Investment-Worthy Enterprise" for its outstanding R&D capabilities and outstanding innovation achievements. In addition, Dr. Wang Zengquan, the company's founder, chairman and general manager, was honored as "2025 Scientist of the Year". With both corporate and individual honors, Technoderma Medicines stands out as a representative example in this year's selection.

About the Selection

The 8th Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Top 50 Selection was organized by the China Innovation Industry Research Institute and hosted by Guangdong Medical Valley. Over several months, it attracted participation from numerous biotech innovation enterprises across China. The award ceremony gathered local government officials, leading industry experts, investment leaders, entrepreneurs, and top-tier media to explore the future development of the Greater Bay Area’s biotech sector.

Since its inception in June 2018, the Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Top 50 Selection has been successfully held for eight consecutive years, evolving into the largest and most dynamic multilateral resource-sharing innovation ecosystem in the Greater Bay Area’s biopharmaceutical sector. The platform has promoted industrial collaboration, cross-border integration, and international cooperation, earning strong recognition and support from government departments, venture capital institutions, biotech enterprises, and the media. Today, it continues to lead the high-quality development of the biotech industry towards clustering, industrialization, and globalization, and serves as a highly authoritative and influential benchmark event.

Why Technoderma Medicines Stood Out

Technoderma Medicines’ designation as the annual "Pioneer Enterprise" was the result of a comprehensive assessment based on innovation strength, product commercialization capability, team structure and competence, operational efficiency, and capital management capabilities. After multiple rounds of screening, Technoderma Medicines won recognition for its cutting-edge technological expertise in dermatological therapeutics, a robust and diversified development pipeline, and broad accessible market potential.

In addition, Technoderma Medicines was also awarded "2025 Annual Investment-Worthy Enterprise", further reaffirming investor confidence in its long-term development potential. Meanwhile, Dr. Wang Zengquan, the company's founder, chairman and general manager, was honored as " 2025 Scientist of the Year " for his high reputation and active contributions in the industry. Collectively, these honors demonstrate the company’s strong innovation-driven capabilities and growing influence in the biopharmaceutical industry.

About Technoderma Medicines

Located in Tianfu International Bio-town, Chengdu, Sichuan Province, Technoderma Medicines, Inc is a clinical-stage biopharmaceutical company focusing on the R&D of innovative therapies. Guided by its vision of "becoming a world-leading innovative R&D platform for dermatological therapeutics ", Technoderma Medicines focuses on developing innovative therapies for major skin-related diseases, such as androgenetic alopecia, atopic dermatitis, psoriasis, systemic lupus erythematosus and scarring. It is dedicated to advancing First-in-Class small-molecule drugs globally, meeting unmet clinical medical needs, and delivering safer, more effective, and more cost- efficient new drug products for global patients.

In recent years, the company's core R&D pipeline has achieved remarkable milestones. Its lead candidates - TDM-105795 for androgenetic alopecia and TDM-180935 for atopic dermatitis - have both completed Phase IIa clinical trials in the United States. Both programs demonstrated positive efficacy outcomes, favorable tolerability, and strong safety profiles, laying a solid foundation for subsequent clinical development and potential commercialization. These results mark significant progress toward technological breakthroughs in the treatment of related diseases.

Technoderma Medicines’ accomplishments reflect the growing innovative capacity China’s biopharmaceutical enterprises and align closely with the positioning of the Greater Bay Area Biotech Innovation Top 50 Selection. As the company continues to advance its R&D programs toward late-stage clinical development and commercialization, it is expected to inject strong momentum into the high-quality growth of the biotech industry in the Greater Bay Area and across the nation. By contributing differentiated, mechanism-driven solutions in dermatology, Technoderma Medicines is poised to deliver impactful “Chinese innovations” to the global field of skin disease therapeutics.